Evaluation of Extracorporeal Shockwave Therapy and Complex Decongestive Therapy Results in Patients With Lipedema
Evaluation of Extracorporeal Shockwave Therapy (ESWT) and Complex Decongestive Therapy (CDT) Results in Patients With Lipoedema
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Mihrinur Dilvin TÜRKÖZ
- Phone Number: +905054696869
- Email: m.dilvinseker@gmail.com
Study Contact Backup
- Name: Zerrin KASAP
- Phone Number: +905554165266
- Email: drzerrinkasap@gmail.com
Study Locations
-
-
-
Giresun, Turkey (Türkiye)
- Giresun University Training and Research Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Female
- 18 years or older
- Being diagnosed with lipedema according to Wold criteria
- Having type 1, 2 and 3 lipedema
- Having stage 1, 2 and 3 lipedema
Exclusion Criteria:
- Known rheumatic, endocrinological, neuromuscular, dermatological disease, kidney failure, liver failure and malignancy
- Having undergone surgery for lipedema
- Having poor circulation, open wound or infection in the lower extremities
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Complex Decongestive Therapy
In this group, Complex Decongestive Therapy treatment will be applied to both lower extremities for two weeks, three sessions per week.
|
Complex decongestive therapy (CDT) is one of the most important treatment modalities of choice for patients with this clinical condition.
CDT has two phases: treatment and maintenance.
The first stage consists of skin care, manual lymph drainage, kinesiotherapy and bandaging of the limb.
Drainage can facilitate the return of lymphatic flow by stimulating the cisterna chyli.
Next, kinesiotherapy is applied, which aims to activate the lymph.
Finally, the limb is moistened and then a compressive bandage is applied aimed at creating a pressure gradient towards the areas where lymph absorption is greater.
The second phase continues skin care, physical exercises and external compression applications using bandages with varying degrees of elasticity.
|
|
Experimental: Extracorporeal Shockwave Therapy
This group will receive therapy for two weeks, three sessions per week, with the Modus ESWT® Radial Shockwave Therapy ( İnceler Medikal, Turkey ) brand ESWT device (35mm radial wavy head); 3000 impulse 15 Hz will be applied to both lower extremities with an average energy level of 3.5.
|
Shock wave therapy is a new modality for the improvement of cellulite and lipedema; it is an easy, noninvasive, local therapy, without side effects, with short periods of application.
Its original idea was the stimulation of lipid mobilization and improved lipolysis in areas with edema.
|
|
Experimental: Extracorporeal Shockwave Therapy and Complex Decongestive Therapy
In this group, first Extracorporeal Shockwave Therapy and then Complex Decongestive Therapy treatment will be applied in the same session for two weeks, three sessions a week.
|
Complex decongestive therapy (CDT) is one of the most important treatment modalities of choice for patients with this clinical condition.
CDT has two phases: treatment and maintenance.
The first stage consists of skin care, manual lymph drainage, kinesiotherapy and bandaging of the limb.
Drainage can facilitate the return of lymphatic flow by stimulating the cisterna chyli.
Next, kinesiotherapy is applied, which aims to activate the lymph.
Finally, the limb is moistened and then a compressive bandage is applied aimed at creating a pressure gradient towards the areas where lymph absorption is greater.
The second phase continues skin care, physical exercises and external compression applications using bandages with varying degrees of elasticity.
Shock wave therapy is a new modality for the improvement of cellulite and lipedema; it is an easy, noninvasive, local therapy, without side effects, with short periods of application.
Its original idea was the stimulation of lipid mobilization and improved lipolysis in areas with edema.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Dual-energy X-ray absorptiometry (DXA)
Time Frame: measurements will be taken before treatment and at the 2nd week after treatment.
|
DXA measurements were made with the patient in the supine position, with a radiation dose of 5.08 μSv, voltage 83.00 Kv, and current 0.2 mA from the head-to-heel distance by Osteosys Primus brand DXA device (Primus, X-ray densitometer, Osteosys Co. Ltd., Guro-gu, Seoul, Korea) will be made.
With this measurement, the radiation dose received by the patient is very low and is below the daily natural radiation dose (7 μSv).
With the obtained values, leg FM/total FM, android/gynoid fat ratios and fat mass (FM, fat mass) will be calculated using Osteosys Primus version 1.2.0 software.
As a result of DXA measurements of the patients, Body Composition, Fat Mass, leg FM/total FM, Android/Gynoid FM values will be compared.
|
measurements will be taken before treatment and at the 2nd week after treatment.
|
|
Volume measurement
Time Frame: measurements will be taken before treatment and at the 2nd week after treatment.
|
For volume measurements in the lower extremities of the patients, circumference measurements will be taken from the ankle to the thigh at 4 cm intervals; then these values will be calculated automatically with the Pythagorean theorem in the Excel program.
|
measurements will be taken before treatment and at the 2nd week after treatment.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quality of life - Nottingham Health Profile (NHP):
Time Frame: measurements will be taken before treatment and at the 2nd week after treatment.
|
Nottingham Health Profile (NHP) is a general quality of life questionnaire that evaluates patients' perceptions of health problems and the effects of these problems on patients' activities of daily living.
Pain, emotional reactions, sleep, social isolation, physical abilities and energy level subscales are evaluated.
For each subscale, 0 points corresponds to the best health profile and 100 points corresponds to the worst health profile.
The total NHP score is obtained by summing the subscale scores.
|
measurements will be taken before treatment and at the 2nd week after treatment.
|
|
Algometric measurements
Time Frame: measurements will be taken before treatment and at the 2nd week after treatment.
|
The pain threshold of the patients will be measured from the right and left extremities with a Wagner brand manual algometer.
Before the evaluation is made, the patients will be informed about how the measurement will be made, and they will be asked to give information as soon as the feeling of pressure returns to the feeling of pain.
For the measurement, the compression applied by keeping the probe of the algometer device perpendicular to the measuring surface will be gradually increased at the rate of approximately 0.5kg/cm²/s.
The compression applied at the point where the patients feel pain will be terminated.
The measurement will be made twice in the same area and 4 minutes will be waited before the second measurement is taken.
The average of the two measurements will be recorded as the pressure pain threshold.
|
measurements will be taken before treatment and at the 2nd week after treatment.
|
|
Visual Analogue Scale (VAS)
Time Frame: measurements will be taken before treatment and at the 2nd week after treatment.
|
Pain intensity was measured with the Visual Analog Scale (0-10 mm; 0 means no pain, 10 means severe pain), which has a high reliability and validity in measuring musculoskeletal pain.
|
measurements will be taken before treatment and at the 2nd week after treatment.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Mihrinur Dilvin TÜRKÖZ, Giresun University
Publications and helpful links
General Publications
- Aksoy H, Karadag AS, Wollina U. Cause and management of lipedema-associated pain. Dermatol Ther. 2021 Jan;34(1):e14364. doi: 10.1111/dth.14364. Epub 2020 Oct 12.
- Fife CE, Maus EA, Carter MJ. Lipedema: a frequently misdiagnosed and misunderstood fatty deposition syndrome. Adv Skin Wound Care. 2010 Feb;23(2):81-92; quiz 93-4. doi: 10.1097/01.ASW.0000363503.92360.91.
- Siems W, Grune T, Voss P, Brenke R. Anti-fibrosclerotic effects of shock wave therapy in lipedema and cellulite. Biofactors. 2005;24(1-4):275-82. doi: 10.1002/biof.5520240132.
- Brandao ML, Soares HPDS, Andrade MDA, Faria ALSC, Pires RS. Efficacy of complex decongestive therapy for lymphedema of the lower limbs: a systematic review. J Vasc Bras. 2020 May 29;19:e20190074. doi: 10.1590/1677-5449.190074.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neurologic Manifestations
- Connective Tissue Diseases
- Pathological Conditions, Signs and Symptoms
- Skin and Connective Tissue Diseases
- Signs and Symptoms
- Pain
- Lipedema
- Therapeutics
- Physical Therapy Modalities
- Rehabilitation
- Ultrasonic Therapy
- Diathermy
- Hyperthermia, Induced
- Extracorporeal Shockwave Therapy
Other Study ID Numbers
Other Study ID Numbers
- 13.03.2023/16
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.